Institutional members access full text with Ovid®

Share this article on:

Immunohistochemical Distinction of Primary Adrenal Cortical Lesions From Metastatic Clear Cell Renal Cell Carcinoma: A Study of 248 Cases

Sangoi, Ankur R. MD*,†; Fujiwara, Mika MD; West, Robert B. MD, PhD†,‡; Montgomery, Kelli D. BA; Bonventre, Joseph V. MD, PhD§; Higgins, John P. MD; Rouse, Robert V. MD†,‡; Gokden, Neriman MD; McKenney, Jesse K. MD

The American Journal of Surgical Pathology: May 2011 - Volume 35 - Issue 5 - p 678–686
doi: 10.1097/PAS.0b013e3182152629
Original Articles

The diagnosis of metastatic clear cell renal cell carcinoma (CC-RCC) can be difficult because of its morphologic heterogeneity and the increasing use of small image-guided biopsies that yield scant diagnostic material. This is further complicated by the degree of morphologic and immunophenotypic overlap with nonrenal neoplasms and tissues, such as adrenal cortex. In this study, a detailed immunoprofile of 63 adrenal cortical lesions, which included 54 cortical neoplasms, was compared with 185 metastatic CC-RCCs using traditional [anticalretinin, CD10, antichromogranin, antiepithelial membrane antigen, anti-inhibin, antimelanA, anticytokeratins (AE1/AE3 and AE1/CAM5.2), antirenal cell carcinoma marker, and antisynaptophysin)] and novel [anticarbonic anhydrase-IX, antihepatocyte nuclear factor-1b, antihuman kidney injury molecule-1 (hKIM-1), anti-PAX-2, anti-PAX-8, antisteroidogenic factor-1 (SF-1), and anti-T-cell immunoglobulin mucin-1] antibodies. Tissue microarray methodology was used to simulate small image-guided biopsies. Staining extent and intensity were scored semiquantitatively for each antibody. In comparing different intensity thresholds required for a “positive” result, a value of ≥2+ was identified as optimal for diagnostic sensitivity/specificity. For the distinction of adrenal cortical lesions from metastatic CC-RCCs, immunoreactivity for the adrenal cortical antigens SF-1 (86% adrenal; 0% CC-RCC), calretinin (89% adrenal; 10% CC-RCC), inhibin (86% adrenal; 9% CC-RCC), and melanA (86% adrenal; 10% CC-RCC) and for the renal epithelial antigens hKIM-1 (0% adrenal; 83% CC-RCC), PAX-8 (0% adrenal; 83% CC-RCC), hepatocyte nuclear factor-1b (0% adrenal; 76% CC-RCC), epithelial membrane antigen (0% adrenal; 78% CC-RCC), and carbonic anhydrase-IX (3% adrenal; 87% CC-RCC) had the most potential use. Use of novel renal epithelial markers hKIM-1 (clone AKG7) and/or PAX-8 and the adrenocortical marker SF-1 in an immunohistochemical panel for distinguishing adrenal cortical lesions from metastatic CC-RCC offers improved diagnostic sensitivity and specificity.

*Department of Pathology, El Camino Hospital, Mountain View

Department of Pathology, Stanford University, Stanford

Department of Pathology, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA

§Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR

Presented in part at the 98th meeting of the United States and Canadian Academy of Pathology, Boston, MA, March 2009

Correspondence: Ankur R. Sangoi, MD, Department of Pathology, El Camino Hospital, GC-33, Mountain View, CA, 94040 (e-mail: asangoi2@yahoo.com).

© 2011 Lippincott Williams & Wilkins, Inc.